∙ Arm A (advanced solid tumors)

• Having signed and dated the informed consent form.

• Females or males \> 18 years old.

• Histologically or cytologically confirmed advanced solid tumors refractory to standard of care therapy, or for which no standard of care therapy is available.

• Disease that is measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or Response Assessment in Neuro-Oncology (RANO) criteria (for CNS tumors).

• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

• Adequate organ function as defined by the following criteria:

‣ Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 3 × upper limits of normal (ULN), unless liver metastases present, then ≤ 5 × ULN

⁃ Total serum bilirubin ≤ 1.5 × ULN unless bilirubin elevation is related to Gilbert's Syndrome for which bilirubin ≤ 3 × ULN

⁃ Absolute neutrophil count (ANC) ≥ 1,000/μL

⁃ Platelets ≥ 75,000/μL

⁃ Hemoglobin ≥ 8.0 g/dL

⁃ Non-indexed estimated glomerular filtration rate (eGFR) ≥ 50 mL/min/1.73 m2 × BSA (m2)/1.73.

• Transfusion is not allowed to meet entry criteria.

• QTcF ≤ 480 msec

• Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures.

∙ Arm B (newly diagnosed GBM)

• Having signed and dated the informed consent form.

• Females or males \> 18 years old.

• Newly diagnosed, histologically confirmed glioblastoma, non-resectable, partially resected or resected.

• Karnofsky performance status (KPS) ≥ 60 at screening and before the initiation (Day 1) of concomitant therapy.

• Disease that is measurable or evaluable as defined by Response Assessment in Neuro-Oncology (RANO) criteria.

• Adequate organ function as defined by the following criteria:

‣ Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 3 × upper limit of normal (ULN), unless liver metastases present, then ≤ 5 × ULN

⁃ Total serum bilirubin ≤ 1.5 × ULN unless bilirubin elevation is related to Gilbert's Syndrome for which bilirubin ≤ 3 × ULN

⁃ Absolute neutrophil count (ANC) ≥ 1,500/μL

⁃ Platelets ≥ 100,000/μL

⁃ Hemoglobin ≥ 8.0 g/dL

⁃ Non-indexed estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2 × BSA (m2)/1.73.

• Transfusion is not allowed to meet entry criteria.

• QTcF ≤ 480 msec

• Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures.